Propranolol Pediatric Dose — Cardiovascular Indications
Propranolol is a non-selective beta-adrenergic receptor blocker that reduces heart rate, myocardial contractility, and blood pressure by competitively antagonizing catecholamines at β₁ and β₂ receptors. It is used in pediatric patients for a range of cardiovascular indications including supraventricular tachycardia (SVT), hypertension, hypertrophic obstructive cardiomyopathy, and tetralogy of Fallot hypercyanotic spells. Both oral and intravenous formulations are available for use across age groups in monitored settings.
Pediatric Dosing
| Route | Dose | Frequency | Maximum |
|---|---|---|---|
| Oral (PO) | 0.5–1 mg/kg/day divided | Every 6–12 hours | 8 mg/kg/day |
| Intravenous (IV) | 0.01–0.1 mg/kg/dose | Every 6–12 hours | Infants: 1 mg/dose; Children: 3 mg/dose |
For oral dosing, the daily dose is divided into individual doses given every 6 to 12 hours depending on clinical response and tolerance. Worked example (PO): For a 10 kg child receiving 1 mg/kg/day divided every 8 hours: 10 × 1 mg/kg/day = 10 mg/day ÷ 3 doses = approximately 3.3 mg per dose (not to exceed 8 mg/kg/day total).
Worked example (IV): For a 10 kg child using 0.05 mg/kg/dose: 10 × 0.05 mg/kg = 0.5 mg IV per dose. For infants, the single-dose maximum is capped at 1 mg regardless of weight-based calculation; for children, the cap is 3 mg/dose. Consult institutional protocol for titration guidance.
Indications and Clinical Context
Propranolol is employed in pediatric cardiovascular management for conditions requiring beta-adrenergic blockade, including rate control in supraventricular tachycardia, management of hypertension, mitigation of outflow tract obstruction in hypertrophic cardiomyopathy, and acute treatment of tetralogy of Fallot hypercyanotic (“tet”) spells. Its non-selective profile provides both cardiac and peripheral effects, which must be weighed against risks in individual patients.
In the acute inpatient or PICU setting, IV administration allows rapid titration under continuous cardiac monitoring. Oral propranolol is typically reserved for stable outpatient or step-down management. Dosing should be guided by clinical response, heart rate trends, and blood pressure monitoring; practitioners should reference current institutional or subspecialty cardiology protocols when initiating therapy.
Administration and Monitoring
IV propranolol should be administered slowly over at least 10 minutes with continuous cardiac monitoring, given the risk of bradycardia, heart block, and hypotension. The weight-based dose must not exceed the absolute single-dose cap: 1 mg in infants and 3 mg in children. Oral doses should be given consistently with respect to food timing. Key monitoring parameters include heart rate, blood pressure, blood glucose (particularly in neonates and infants, given risk of hypoglycemia), and signs of bronchospasm.
- Contraindications: Decompensated heart failure, cardiogenic shock, significant bradycardia or heart block, reactive airway disease (relative contraindication due to β₂ blockade), and known hypersensitivity.
- Adverse effects: Bradycardia, hypotension, bronchospasm, hypoglycemia, fatigue, and cold extremities.
- Abrupt discontinuation: Avoid sudden cessation in patients on chronic therapy; taper per subspecialty guidance.
- Consult institutional protocol for concentration, diluent, and infusion rate specifics for IV use.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.